Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

52.88 -4.83 (-8.37%)

Streaming Delayed Price Updated: 11:37 AM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 25, 2023

Via Benzinga

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

April 25, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results

April 18, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Is Arrowhead Pharmaceuticals a Buy Now? ↗

April 16, 2023

The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.

Via The Motley Fool

Expert Ratings for Arrowhead Pharma ↗

April 12, 2023

Via Benzinga

Analyst Ratings for Arrowhead Pharma ↗

March 21, 2023

Via Benzinga

Arrowhead Pharmaceuticals's Return On Capital Employed Overview ↗

February 07, 2023

Via Benzinga

Earnings Outlook For Arrowhead Pharmaceuticals ↗

February 03, 2023

Via Benzinga

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Making Surprising Moves in Thursday Session

April 13, 2023

Via Investor Brand Network

Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' ↗

April 12, 2023

SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...

Via Benzinga

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Highlighted for Surprising Price Action

April 12, 2023

Via Investor Brand Network

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics

April 12, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street ↗

April 04, 2023

Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.

Via The Motley Fool

Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 12, 2023

Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in...

Via Benzinga

First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead

April 04, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023 ↗

April 12, 2023

Via Benzinga

Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK

April 03, 2023

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

March 31, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Want Diversified Upside in Biotechnology? Check out LABU

March 22, 2023

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.

Via MarketBeat

Topics ETFs Stocks

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

Arrowhead Receives FDA Fast Track Designation for ARO-APOC3

March 20, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference

March 03, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

February 28, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals ↗

February 15, 2023

Via Benzinga

Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

February 15, 2023

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results

February 06, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 06, 2023

Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54.

Via Benzinga

Energizer, Children's Place And Other Big Stocks Moving Lower On Monday ↗

February 06, 2023

U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Earnings Scheduled For February 6, 2023 ↗

February 06, 2023

Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.

Via Benzinga

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

February 02, 2023

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today